Toxicity, dosage, and efficacy of vinorelbine (navelbine) in dogs with spontaneous neoplasia

Journal of Veterinary Internal Medicine

Volumn 18, Issue 4, 2004, Pages 536-539

  Poirier, Valerie J ^a   Burgess, Kristine E ^a   Adams, William M ^a,b   Vail, David M ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Cancer; Canine; Chemotherapy; Phase I; Vinca alkaloid

Indexed keywords

NAVELBINE;

ARTICLE; BLOOD TOXICITY; CONTROLLED STUDY; DOG DISEASE; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; LUNG ALVEOLUS CELL CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; NEOPLASM; NEUTROPENIA; NONHUMAN; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOG DISEASES; DOGS; FEMALE; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; RECORDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINBLASTINE; WISCONSIN;

CANIS FAMILIARIS; VINCA;

EID: 4243200414     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2004)18<536:TDAEOV>2.0.CO;2     Document Type: Article

References (21)

1. Rowinsky EK, Donehower RC. Antimicrotubule agents. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy, 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:330-343.
2. Jordan MA, Thower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 1991;51:2212-2222.
3. Burris HA, Fields S. Summary of data from in vitro and phase I vinorelbine (Navelbine) studies. Semin Oncol 1994;21(5 Suppl 10):14-19.
4. Mathe G, Reizenstein P. Phase I pharmacologic study of a new Vinca alkaloid: Navelbine. Cancer Lett 1985;27(3):285-293.
5. Wozniak AJ. Single-agent vinorelbine in the treatment of non-small cell lung cancer. Semin Oncol 1999;26(5 Suppl 16):71-72.
6. Zelek L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001;92:2267-2272.
7. Sorensen P, Hoyer M, Jakobsen A, et al. Phase II study of vinorelbine in the treatment of platinum resistant ovarian carcinoma. Gynecol Oncol 2001;81:58-62.
8. Bidoli P Stani SC, De Candis D, et al. Single-agent chemotherapy with vinorelbine for pretreated or metastatic squamous cell carcinoma of the eosophagus. Tumori 2001;87(5):299-302.
9. Balzarotti M, Santoro A, Tondini C, et al. Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma. Ann Oncol 1996;7:970-972.
10. Nasti G, Errante D, Talamini R, et al. Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: Results of a phase II study. J Clin Oncol 2000;18:1550-1557.
11. Steele JP, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000;18:3912-3917.
12. Pace A, Bove L, Nistico C, et al. Vinorelbine neurotoxicity: Clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psychiatry 1996;61:409-411.
13. Colleoni M, Gaion F, Vicario G, et al. Pain at tumor site after vinorelbine injection: Description of an unexpected side effect. Tumori 1995;81(3):194-196.
14. Karminsky N, Merimsky O, Kovner F, et al. Vinorelbine-related acute cardiopulmonary toxicity. Cancer Chemother Pharmacol 1999;43:180-182.
15. Cicchetti S, Jemec B, Gault DT. Two case reports of vinorelbine extravasation: Management and review of the literature. Tumori 2000;86:289-292.
16. Rrikoran A, Rahmani R, Bromet M, et al. Pharmacokinetics and metabolism of Navelbine. Semin Oncol 1989;16(Suppl 4):21.
17. Leveque D, Quoix E, Dumont P, et al. Pulmonary distribution of vinorelbine in patients with non-small-cell lung cancer. Cancer Chemother Pharmacol 1993;33:176-178.
18. Leveque D, Jehl F. Clinical pharmacokinetics of vinorelbine. Clin Pharmacokinet 1997;32:184-197.
19. Kobayashi S, Sakai T, Dalrymple PD, et al. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. Arzneimittelforschung 1993;43:1367-1377.
20. Thamm DH, MacEwen EG, Phillips BS, et al. Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia. Cancer Chemother Pharmacol 2002;49:251-255.
21. Thamm DH, Mauldin EA, Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor-41 cases (1992-1997). J Vet Intern Med 1999;13:491-497.